Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma-Reference-Cited by-同舟云学术

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma

Published:2022-05-05 Issue:3 Volume:40 Page:356-369
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Liu Xiaoqian¹²,Xu Senlin²^ORCID,Zhang Jiawei²,Fan Mingjie²,Xie Jun³,Zhang Bingfeng³,Li Hongzhi³,Yu Guohua⁴,Liu Yinghui¹,Zhang Yuanfeng¹^ORCID,Song Joo⁵,Horne David³,Chan Wing C.⁵,Chu Xiaoxia¹^ORCID,Huang Wendong²^ORCID

Affiliation:

1. Department of Hematology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong China

2. Molecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism Beckman Research Institute City of Hope Duarte California USA

3. Department of Molecular Medicine City of Hope National Medical Center Duarte California USA

4. Department of Pathology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong China

5. Department of Pathology City of Hope National Medical Center Duarte California USA

Funder

National Cancer Institute

City of Hope

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3010

Reference40 articles.

1. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

2. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

3. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological profiling of a berbamine derivative for lymphoma treatment;Blood Advances;2024-01-10